Clinical Trials
129 trialsGRECCAR12
University Hospital, Bordeaux
COLOCROSS
Centre Oscar Lambret
KEYNOTE-585
Merck Sharp & Dohme LLC
KEYNOTE-585
Merck Sharp & Dohme LLC
MECCA
Sun Yat-sen University
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Daiichi Sankyo
KEYNOTE-859
Merck Sharp & Dohme LLC
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
National Cancer Institute (NCI)
GRECCAR8
Hospices Civils de Lyon
MK-3475-811
Merck Sharp & Dohme LLC
IMpassion132
Hoffmann-La Roche
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
Jiangsu HengRui Medicine Co., Ltd.
PRECIOUS
Japan Breast Cancer Research Group
CinClare
Fudan University
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
Novartis
CheckMate649
Bristol-Myers Squibb
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer
Peking Union Medical College Hospital
Néofirinox
UNICANCER
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
LYNK-003
Merck Sharp & Dohme LLC
TROPiCS-02
Gilead Sciences
PEARL
Spanish Breast Cancer Research Group
Study of Adjuvant ONO-4538 With Resected Gastric Cancer
Ono Pharmaceutical Co., Ltd.
TULIP
Byondis B.V.
NACRE
UNICANCER
Keynote-122
Merck Sharp & Dohme LLC
Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
MK-3475-062
Merck Sharp & Dohme LLC
Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
OBELICS
National Cancer Institute, Naples
TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma
Sun Yat-sen University
EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer
Spanish Breast Cancer Research Group
Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients
Spanish Breast Cancer Research Group
Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer
Innovent Biologics (Suzhou) Co. Ltd.
RIBBIT
iOMEDICO AG
MINDACT
European Organisation for Research and Treatment of Cancer - EORTC
Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)
Cancer Trials Ireland
ASCENT
Gilead Sciences
Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
EMD Serono
Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer
Pierre Fabre Medicament
KEYNOTE-119
Merck Sharp & Dohme LLC
Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer
Corporacion Parc Tauli
The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer
Fudan University
Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
Medical Research Council
RAINFALL
Eli Lilly and Company
NALA
Puma Biotechnology, Inc.
Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal Cancer
UNICANCER
RectumSIB
Universitair Ziekenhuis Brussel